Search Results 491-500 of 18035 for Alopecia

1. A Study to Test the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors - Mayo Clinic

   The patient must have recovered to baseline or CTCAE ≤ Grade 1 from toxicity due to all prior therapies except alopecia, neuropathy and other non ...

2. A Study to Evaluate Olaparib and Temozolomide in Treating Patients With Advanced, Metastatic, or Unresectable Uterine Leiomyosarcoma - Mayo Clinic

   ... alopecia. Patients who have endocrinopathies associated with prior immunotherapy treatment but which are controlled with replacement therapy are eligible ...

3. MC200404, Safety and Immunogenicity of PolyPEPI1018 Vaccine in the Treatment of Late-stage Metastatic Colorectal Cancer - Mayo Clinic

   Relevant toxicities of prior therapies must have resolved to ≤Grade 1, except for oxaliplatin-related neuropathy or alopecia;; Participant with myocardial ...

4. A Study Assessing the Effectiveness and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced Triple Negative Breast Cancer - Mayo Clinic

   Subject has not recovered from all toxicities related to prior anticancer therapies to NCI CTCAE version 4.03 Grade ≤ 1; with the exception of alopecia.

5. Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye - Mayo Clinic

   ... alopecia and other non-clinically significant adverse events (AEs); No active brain metastases or epidural disease; patients with brain metastases previously ...

6. Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors - Mayo Clinic

   Adverse events due to previous anti-tumor therapy have not recovered to ≤ CTCAE Grade 1, except alopecia and peripheral neurotoxicity with ≤ CTCAE Grade 2.

7. A Study to Evaluate Trabectedin with Olaparib in Advanced Unresectable or Metastatic Sarcoma - Mayo Clinic

   Persistent toxicities (>Common Terminology Criteria for Adverse Event (CTCAE) grade 2) caused by previous cancer therapy, excluding alopecia. Patients with ...

8. Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors - Mayo Clinic

   Note: Except patients with ≤ Grade 2 neuropathy or any grade of alopecia. Has tumor(s) invading a major vascular structure (e.g., carotid artery) or other ...

9. A Study to Evaluate Ulixertinib to Treat Patients with Advanced Malignancies Harboring MEK or Atypical BRAF Alterations - Mayo Clinic

   In addition, any drug-related toxicity except alopecia should have recovered to Grade 1 or less. Prior therapy with any ERK inhibitor (e.g., LY3214996 ...

10. A Study Comparing Gemcitabine with or without AZD 1775 in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer - Mayo Clinic

    ... alopecia or peripheral neuropathy can also be included; Palliative radiation to < 10% of bone marrow is permissible if completed within one week of ...